Clinical trial
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients…
NCT00069966 · Theradex, Industry · Unknown status
Key facts
| NCT number | NCT00069966 |
|---|---|
| Title | Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse |
| Official title | A Phase II Trial of BBR 2778 in Combination With Cytarabine, Methylprednisolone and Cisplatin (BSHAP) as Salvage in Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma |
| Lead sponsor | Theradex, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug, Procedure |
| Interventions | filgrastim, rituximab, cisplatin, cytarabine, methylprednisolone, pixantrone dimaleate, autologous bone marrow transplantation, peripheral blood stem cell transplantation |
| Start date | Apr 1, 2003 |
| First posted | Oct 7, 2003 |
| Last update posted | Jul 7, 2009 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: